Bulletin 79: Branded mesalazine prescribing

Following a review of the literature, changes have been made to the recommendations on interchangeability of oral mesalazine preparations. The BNF now states that there is no evidence to show that any one oral preparation of mesalazine is more effective than another. This bulletin reviews the cost of prescribing mesalazine MR generically and as the Asacol® brand, and offers guidance and support to organisations who wish to recommend the prescribing of branded Octasa® MR tablets to release savings to the prescribing budget.

Loading...